Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389155 · ClinicalTrials.gov registry record · Phase 2
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Phase 2 study of Bladder Cancer and Metastasis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 20
- Study locations
NCT00389155 is a Phase 2 study of Bladder Cancer and Metastasis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 34 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00389155, a Phase 2 study of Bladder Cancer and Metastasis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test an investigational drug, vinflunine (BMS-710485), in combination with gemcitabine in patients with Transitional Cell Carcinoma who cannot be treated with cisplatin. This study will help to determine whether vinflunine in combination with gemcitabine will extend the time period until further growth of the tumor more than gemcitabine alone.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Gemcitabine
- DRUG Vinflunine
Study Locations (20)
California
- Tower Hematology Oncology Medical Group - Beverly Hills
- Local Institution - Concord
- Glendale Memorial Hospital And Health Center - Glendale
- Moores Ucsd Cancer Center - La Jolla
- North Valley Hematology/Oncology Medical Group - Mission Hills
- Local Institution - Orange
- Stanford University - Stanford
Florida
- University Of Florida College Of Medicine At Jacksonville - Jacksonville
- Local Institution - Jacksonville
- Lakeland Regional Cancer Center - Lakeland
- University Of Miami - Miami
- Advanced Medical Specialties - Miami
Georgia
- Medical College Of Georgia - Augusta
- Central Georgia Cancer Care, Pc - Macon
Illinois
- University Of Chicago - Chicago
- Springfield Clinic, Llp - Springfield
Alabama
- University Of Alabama At Birmingham - Birmingham
Arizona
- Acrc/Arizona Clinical Research Center, Inc. - Tucson
Delaware
- Local Institution - Newark
Indiana
- Michiana Hematology Oncology, P.C. - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389155
The ClinicalTrials.gov registry entry for NCT00389155 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00389155 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00389155 about?
NCT00389155 is a clinical study titled "First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy". The purpose of this study is to test an investigational drug, vinflunine (BMS-710485), in combination with gemcitabine in patients with Transitional Cell Carcinoma who cannot be treated with cisplatin. This study will help to determine whether vinflunine in combination with gemcitabine will extend t...
What is the current status of trial NCT00389155?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2007-01. Estimated completion is 2008-01.
What conditions does trial NCT00389155 study?
This clinical trial studies the following conditions: Bladder Cancer, Metastasis, Transitional Cell Carcinoma.
What interventions are being tested in trial NCT00389155?
The interventions under investigation include: Placebo (OTHER), Gemcitabine (DRUG), Vinflunine (DRUG).
Who is sponsoring clinical trial NCT00389155?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00389155 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.